Epizyme
$9.599876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$9.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.07 (-0.72%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell Epizyme and other stocks, options, and ETFs commission-free!
About EPZM
Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. The listed name for EPZM is Epizyme, Inc. Common Stock.
CEO
Robert B. Bazemore
Employees
304
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
1.05B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
956.20K
High Today
$9.86
Low Today
$9.42
Open Price
$9.72
Volume
1.16M
52 Week High
$23.61
52 Week Low
$9.42
EPZM News
Analyst Ratings
63%
of 8 ratings
Buy
63%
Hold
38%
Sell
0%
EPZM Earnings
-$0.74
-$0.49
-$0.25
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.58 per share
Actual
-$0.65 per share